Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;39(9):2304-2305.
doi: 10.1038/s41375-025-02721-4. Epub 2025 Aug 4.

Author's Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al

Simone Cesaro  1 , Per Ljungman  2   3 , Malgorzata Mikulska  4 , Hans H Hirsch  5 , David Navarro  6 , Catherine Cordonnier  7 , Varun Mehra  8 , Jan Styczynski  9 , Francesco Marchesi  10 , Jose Luis Pinana  11 , Gernot Beutel  12 , Herman Einsele  13 , Johan Maertens  14 ; ECIL-10; Rafael de la Camara  15
Collaborators, Affiliations

Author's Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al

Simone Cesaro et al. Leukemia. 2025 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. The European Conference on Infections in Leukemia (ECIL): ECIL is a society cofounded by the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation ( https://www.ebmt.org/working-parties/infectious-diseases-working-party-idwp ), the International Immunocompromised Host Society (ICHS) ( https://www.ichs.org/ ), the European Leukemia Net (ELN) ( https://www.leukemia-net.org/ ), and the European Organisation for Research and Treatment of Cancer (EORTC).

References

    1. Focosi D, Casadevall A, Sullivan DJ, Joyner MJ, Franchini M. ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration. Leukemia. 2025;39. https://doi.org/10.1038/s41375-025-02691-7 .
    1. Cesaro S, Ljungman P, Mikulska M, Hirsch HH, Navarro D, Cordonnier C, et al. Postpandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10). Leukemia. 2025. https://doi.org/10.1038/s41375-025-02649-9 .
    1. Hoffmann S, Schrezenmeier E, Desmarets M, Halleck F, Durrbach A, Peters L, et al. Early,very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial. EBioMedicine. 2025;113:105613. - PubMed - PMC
    1. Zaremba S, Focosi D, Pruter WW, Franchini M, Collantes Hoyos DB, Cruciani M, et al. Convalescent plasma treatment of B-cell depleted patients with COVID-19: systematic review and individual participant data meta-analysis. MedRxiv. 2025. https://doi.org/10.1101/2025.05.15.25327576 .

LinkOut - more resources